Rong-Hui Li

Pharmacological targeting of FKBPL with rapamycin sensitizes triple-negative breast cancer to ferroptosis.

Triple-negative breast cancer (TNBC) remains a clinically formidable subtype, while resistant to conventional apoptotic cell death pathways, it exhibits a unique and exploitable vulnerability to ferroptosis. Here, we identify the FK506-binding protein-like (FKBPL) as a novel scaffold that dictates ferroptosis sensitivi...